PMID- 34018464
OWN - NLM
STAT- MEDLINE
DCOM- 20210607
LR  - 20221207
IS  - 1532-2513 (Electronic)
IS  - 0892-3973 (Print)
IS  - 0892-3973 (Linking)
VI  - 43
IP  - 3
DP  - 2021 Jun
TI  - Anti-IgE monoclonal antibodies as potential treatment in COVID-19.
PG  - 259-264
LID - 10.1080/08923973.2021.1925906 [doi]
AB  - Coronavirus disease 2019 (COVID-19) is associated with irreversible effects on 
      vital organs, especially the respiratory and cardiac systems. While the immune 
      system plays a key role in the survival of patients to viral infections, in 
      COVID-19, there is a hyperinflammatory immune response evoked by all the immune 
      cells, such as neutrophils, monocytes, and includes release of various cytokines, 
      resulting in an exaggerated immune response, named cytokine storm. This severe, 
      dysregulated immune response causes multi-organ damage, which eventually leads to 
      high mortality. One of the most important components of hypersensitivity is 
      immunoglobulin E (IgE), which plays a major role in susceptibility to respiratory 
      infections and can lead to the activation of mast cells. There is also a negative 
      association between IgE and IFN-alpha, which can reduce Toll-like receptor (TLR) nine 
      receptor expression and TLR-7 signaling to disrupt IFN production. Moreover, 
      anti-IgE drugs such as omalizumab reduces the severity and duration of COVID-19. 
      In addition to its anti-IgE effect, omalizumab inhibits inflammatory cells such 
      as neutrophils. Hence, blockade of IgE may have clinical utility as an 
      immunotherapy for COVID-19.
FAU - Farmani, Ahmad Reza
AU  - Farmani AR
AUID- ORCID: 0000-0003-1149-3843
AD  - Tissue Engineering and Applied Cell Sciences Department, School of Advanced 
      Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
AD  - Tissue Engineering Department, School of Advanced Technologies in Medicine, Fasa 
      University of Medical Sciences, Fasa, Iran.
AD  - Students' Scientific Research Center, Tehran University of Medical Sciences, 
      Tehran, Iran.
FAU - Mahdavinezhad, Forough
AU  - Mahdavinezhad F
AD  - Anatomy Department-School of Medicine, Tehran University of Medical Sciences, 
      Tehran, Iran.
FAU - Moslemi, Rohollah
AU  - Moslemi R
AD  - Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical 
      Sciences, Shiraz, Iran.
FAU - Mehrabi, Zeinab
AU  - Mehrabi Z
AD  - Internal Medicine Department, School of Medicine, Shiraz University of Medical 
      Sciences, Shiraz, Iran.
FAU - Noori, Alireza
AU  - Noori A
AD  - Tissue Engineering and Applied Cell Sciences Department, School of Advanced 
      Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Kouhestani, Mahsa
AU  - Kouhestani M
AD  - Tissue Engineering and Applied Cell Sciences Department, School of Advanced 
      Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Noroozi, Zahra
AU  - Noroozi Z
AD  - Department of Molecular Medicine, School of Advanced Technologies in Medicine, 
      Tehran University of Medical Sciences, Tehran, Iran.
FAU - Ai, Jafar
AU  - Ai J
AD  - Tissue Engineering and Applied Cell Sciences Department, School of Advanced 
      Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
FAU - Rezaei, Nima
AU  - Rezaei N
AUID- ORCID: 0000-0002-3836-1827
AD  - Research Center for Immunodeficiencies, Children's Medical Center, Tehran 
      University of Medical Sciences, Tehran, Iran.
AD  - Department of Immunology, School of Medicine, Tehran University of Medical 
      Sciences, Tehran, Iran.
AD  - Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal 
      Scientific Education and Research Network (USERN), Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Video-Audio Media
DEP - 20210521
PL  - England
TA  - Immunopharmacol Immunotoxicol
JT  - Immunopharmacology and immunotoxicology
JID - 8800150
RN  - 0 (Interferon-alpha)
RN  - 0 (TLR7 protein, human)
RN  - 0 (Toll-Like Receptor 7)
RN  - 2P471X1Z11 (Omalizumab)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - COVID-19/*immunology
MH  - Humans
MH  - Immunoglobulin E/immunology
MH  - Interferon-alpha/immunology
MH  - Omalizumab/immunology/*therapeutic use
MH  - Signal Transduction/*drug effects/immunology
MH  - Toll-Like Receptor 7/immunology
MH  - *COVID-19 Drug Treatment
PMC - PMC8146297
OTO - NOTNLM
OT  - COVID-19
OT  - IgE
OT  - hyperinflammation
OT  - hypersensitivity
OT  - immunity system
OT  - omalizumab
COIS- No potential conflict of interest was reported by the author(s).
EDAT- 2021/05/22 06:00
MHDA- 2021/06/08 06:00
PMCR- 2021/05/25
CRDT- 2021/05/21 08:41
PHST- 2021/05/22 06:00 [pubmed]
PHST- 2021/06/08 06:00 [medline]
PHST- 2021/05/21 08:41 [entrez]
PHST- 2021/05/25 00:00 [pmc-release]
AID - 1925906 [pii]
AID - 10.1080/08923973.2021.1925906 [doi]
PST - ppublish
SO  - Immunopharmacol Immunotoxicol. 2021 Jun;43(3):259-264. doi: 
      10.1080/08923973.2021.1925906. Epub 2021 May 21.